Andrew Gibbons

Pharmaceutical Operations Executive | Associate Director of Clinical and Commercial Supply at Foresee Pharmaceuticals

Role: Associate Director of Clinical and Commercial Supply Chain at Foresee Pharmaceuticals
Location: Philadelphia, PA, US
LinkedIn followers: 500 followers

Supply Chain & LogisticsView LinkedIn profile

About Andrew Gibbons

Senior life sciences operations leader with 15+ years of experience in life sciences and provider. Expertise in global program and project management, R&D, supply chain, and operating models. Proven record of driving large-scale, cross-functional initiatives and transformation that enhance efficiency, business operations, and value. Adept at partnering with senior stakeholders to deliver strategic solutions, optimize end-to-end processes, and build sustainable capabilities. Experienced in standing up new functions, optimizing operating models, and instilling change.Deep knowledge of the life sciences space spanning more than a decade of clinical research across numerous therapeutic areas (oncology, cardiovascular, general medicine). An experienced leader who delivers results, driven by a passion for operational excellence and flawless execution. AREAS OF EXPERTISE: Clinical Operations & Research • Transformation • Trial Management & Delivery • Supply Chain • Global Program Management • ICH / GCP Regulatory Compliance • Supplier / Vendor Management • Budgeting & Forecasting • Standard Operating Procedures (SOPs) • Cross-Functional Leadership

Experience

Associate Director of Clinical and Commercial Supply Chain
Foresee Pharmaceuticals
Apr 2024 — Present · Philadelphia, PA, US
Lead clinical and commercial supply strategy and operations.

Education

Temple University
Bachelor of Science (B.S.)

Skills

Negotiation
Management
Microsoft Office
Strategic Planning
Customer Service
Leadership
Pharmaceutical Industry
Microsoft Excel
Budgets
Clinical Trials
Clinical Research
Study Monitoring
Regulatory Requirements
Oncology
Sop
Protocol
CRO
Clinical Development
Gcp
Ich-Gcp
Ctms
Clinical Monitoring
Edc

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@foreseepharma.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Foresee Pharmaceuticals

Biotechnology Research · 38 employees · Founded 2013 · Taiwan

Foresee Pharmaceuticals is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (TPEx: 6576). Foresee\'s R&D efforts are focused on two key areas, namely its unique Stabilized Injectable Formulation (SIF) long-acting injectable technology with derived drug products targeting specialty markets and secondly, its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee\'s product portfolio includes late and early-stage programs. CAMCEVI 6-month formulation, for the treatment of advanced prostate cancer, is now approved in the U.S, Canada, EU, Taiwan and Israel and launched in the U.S. Additionally, the U.S. NDA for the 3-month version of CAMCEVI has been submitted. For the second indication of CAMCEVI 42 mg, central precocious puberty (CPP), the Casppian phase 3 clinical study, has been initiated. FP-025, a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, has been investigated in a Phase 2 POC study in allergic asthmatic patients. The study has been completed with positive outcomes, with future development in rare immune-fibrotic diseases. FP-020, a follow-on oral MMP-12 inhibitor, for which a Phase 1 study has been completed, with development targeted in severe asthma, COPD and IBD. FP-045 is a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the FuschiA Phase 1b/2 Fanconi Anemia study is currently being initiated, and the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients is in planning with targeted initiation in the fourth quarter of 2024. Building on the compelling biology of ALDH2, and translational data from several Foresee ALDH2 activators, a follow-on candidate from a new series of compounds is being selected for development in metabolic syndrome/healthy weight loss and the broader cardiovascular-renal-metabolic space.

foreseepharma.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Andrew Gibbons

Experience

Associate Director of Clinical and Commercial Supply Chain

Education

Temple University

Skills

Find verified contacts for anyone on LinkedIn